OCGN Ocugen Inc

Ocugen Engages Kemwell Biopharma for cGMP Manufacture of OCU200

Ocugen Engages Kemwell Biopharma for cGMP Manufacture of OCU200
EN
06/10/2020

Underlying

OCGNOcugen Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ocugen Inc

 PRESS RELEASE
Free
OCGN OCUGEN INC

Ocugen Provides Business Update with Fourth Quarter and Full Year 2025...

Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast Today at 8:30 a.m. ET Enrollment for the OCU400 Phase 3 liMeliGhT clinical trial—the first and largest gene therapy registrational trial for broad retinitis pigmentosa patients—was completed. Topline Phase 3 data expected in the first quarter 2027, advancing OCU400 towards potential approval in 2027.OCU410ST Phase 2/3 pivotal confirmatory trial nearing enrollment completion. Interim data expected in the third quarter 2026, followed by topline Phase 2/3 data in the second qu...

March 4, 2026 1 EN
 PRESS RELEASE
Free
OCGN OCUGEN INC

Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a...

Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa Enrollment for liMeliGhT, the first and largest gene therapy registrational trial for broad retinitis pigmentosa (RP) patients, was completed, reflecting strong interest from investigators and patientsTopline Phase 3 data expected in 1Q 2027, advancing OCU400 towards potential approval in 2027 as a treatment option for early- to late-stage RPPositive long-term, 3-year Phase 1/2 durable, safety and tolerability data for OCU400 demonstrates sustained clinically mea...

March 2, 2026 1 EN
 PRESS RELEASE
Free
OCGN OCUGEN INC

Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M...

Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results MALVERN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company’s fourth quarter and full year 2025 financial results and provide a business update at 8:30 a.m. ET on Wednesday, March 4, 2026. Ocugen will issue a pre-market earnin...

February 18, 2026 1 EN
 PRESS RELEASE
Free
OCGN OCUGEN INC

Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment of Rita Johnson-Greene as Chief Financial Officer (CFO). “Mrs. Johnson-Greene’s diverse background across a variety of strategic roles at organizations representing many facets of the industry make her well-suited to serve as Ocugen’s CFO,” said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. “We look forw...

February 9, 2026 1 EN
 PRESS RELEASE
Free
OCGN OCUGEN INC

Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registere...

Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock MALVERN, Pa., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of its previously announced underwritten registered direct offering of 15,000,000 shares of its common stock at an offering price of $1.50 per share of common stock for net proceeds of $20.85 million, after deducting commissions and other estimated offering expenses payable by Ocugen. The financing was led by...

January 23, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch